News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
720,794 Results
Type
Article (52774)
Company Profile (332)
Press Release (667672)
Multimedia
Podcasts (169)
Webinars (25)
Section
Business (199474)
Career Advice (2659)
Deals (36924)
Drug Delivery (140)
Drug Development (82330)
Employer Resources (169)
FDA (17567)
Job Trends (15183)
News (346020)
Policy (34368)
Tag
Academia (2658)
Academic (1)
Accelerated approval (30)
Adcomms (35)
Allergies (132)
Alliances (51838)
ALS (167)
Alzheimer's disease (1738)
Antibody-drug conjugate (ADC) (308)
Approvals (17705)
Artificial intelligence (533)
Autoimmune disease (136)
Automation (33)
Bankruptcy (351)
Best Places to Work (11405)
BIOSECURE Act (23)
Biosimilars (193)
Biotechnology (191)
Bladder cancer (151)
Brain cancer (56)
Breast cancer (611)
Cancer (4598)
Cardiovascular disease (401)
Career advice (2243)
Career pathing (40)
CAR-T (285)
CDC (59)
Cell therapy (756)
Cervical cancer (34)
Clinical research (69631)
Collaboration (1580)
Company closure (5)
Compensation (1081)
Complete response letters (64)
COVID-19 (2875)
CRISPR (91)
C-suite (726)
Cystic fibrosis (145)
Data (5784)
Decentralized trials (2)
Denatured (52)
Depression (129)
Diabetes (483)
Diagnostics (6799)
Digital health (40)
Diversity (12)
Diversity, equity & inclusion (43)
Drug discovery (248)
Drug pricing (205)
Drug shortages (35)
Duchenne muscular dystrophy (222)
Earnings (81037)
Editorial (60)
Employer branding (20)
Employer resources (151)
Events (112270)
Executive appointments (976)
FDA (20458)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1370)
Gene editing (200)
Generative AI (47)
Gene therapy (607)
GLP-1 (1067)
Government (4476)
Grass and pollen (8)
Guidances (377)
Healthcare (18169)
HIV (54)
Huntington's disease (45)
IgA nephropathy (80)
Immunology and inflammation (271)
Immuno-oncology (43)
Indications (76)
Infectious disease (3140)
Inflammatory bowel disease (189)
Inflation Reduction Act (14)
Influenza (111)
Intellectual property (220)
Interviews (487)
IPO (16494)
IRA (57)
Job creations (4142)
Job search strategy (1855)
Kidney cancer (16)
Labor market (78)
Layoffs (627)
Leadership (39)
Legal (8447)
Liver cancer (93)
Longevity (13)
Lung cancer (636)
Lymphoma (357)
Machine learning (39)
Management (59)
Manufacturing (740)
MASH (165)
Medical device (14286)
Medtech (14324)
Mergers & acquisitions (21461)
Metabolic disorders (1282)
Multiple sclerosis (152)
NASH (23)
Neurodegenerative disease (317)
Neuropsychiatric disorders (85)
Neuroscience (2925)
NextGen: Class of 2025 (6434)
Non-profit (3878)
Now hiring (54)
Obesity (622)
Opinion (316)
Ovarian cancer (152)
Pain (189)
Pancreatic cancer (196)
Parkinson's disease (271)
Partnered (32)
Patents (470)
Patient recruitment (418)
Peanut (58)
People (59520)
Pharmaceutical (99)
Pharmacy benefit managers (30)
Phase I (21632)
Phase II (30327)
Phase III (23307)
Pipeline (4012)
Policy (319)
Postmarket research (2658)
Preclinical (9122)
Press Release (71)
Prostate cancer (229)
Psychedelics (53)
Radiopharmaceuticals (278)
Rare diseases (806)
Real estate (6190)
Recruiting (69)
Regulatory (25654)
Reports (43)
Research institute (2467)
Resumes & cover letters (434)
Rett syndrome (24)
RNA editing (14)
RSV (76)
Schizophrenia (148)
Series A (240)
Series B (171)
Service/supplier (17)
Sickle cell disease (100)
Special edition (26)
Spinal muscular atrophy (166)
Sponsored (45)
Startups (3834)
State (2)
Stomach cancer (19)
Supply chain (106)
Tariffs (97)
The Weekly (115)
Vaccines (1089)
Venture capital (82)
Weight loss (437)
Women's health (70)
Worklife (21)
Date
Today (97)
Last 7 days (526)
Last 30 days (2346)
Last 365 days (31583)
2025 (31362)
2024 (36112)
2023 (40654)
2022 (51743)
2021 (55935)
2020 (53829)
2019 (45808)
2018 (34783)
2017 (34097)
2016 (33668)
2015 (38521)
2014 (31568)
2013 (26586)
2012 (28751)
2011 (29242)
2010 (27070)
Location
Africa (877)
Alabama (78)
Alaska (7)
Arizona (280)
Arkansas (12)
Asia (44529)
Australia (7162)
California (10529)
Canada (3017)
China (1051)
Colorado (435)
Connecticut (470)
Delaware (321)
Europe (98501)
Florida (1565)
Georgia (340)
Hawaii (3)
Idaho (59)
Illinois (797)
India (59)
Indiana (495)
Iowa (20)
Japan (397)
Kansas (119)
Kentucky (38)
Louisiana (22)
Maine (77)
Maryland (1361)
Massachusetts (7750)
Michigan (321)
Minnesota (598)
Mississippi (6)
Missouri (129)
Montana (33)
Nebraska (27)
Nevada (117)
New Hampshire (79)
New Jersey (2894)
New Mexico (31)
New York (2776)
North Carolina (1437)
North Dakota (9)
Northern California (5046)
Ohio (306)
Oklahoma (21)
Oregon (43)
Pennsylvania (2108)
Puerto Rico (20)
Rhode Island (41)
South America (1259)
South Carolina (60)
South Dakota (1)
Southern California (4067)
Tennessee (158)
Texas (1624)
United States (37909)
Utah (298)
Vermont (1)
Virginia (257)
Washington D.C. (79)
Washington State (869)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
720,794 Results for "avadel pharma flamel technologies s a acquired avadel".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
A day after Pfizer closed its hotly contested Metsera deal, Lundbeck has made an unsolicited offer to steal Avadel Pharmaceuticals away from Alkermes.
November 14, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to go with its original suitor.
November 19, 2025
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’
With Avadel under its fold, Alkermes expects to accelerate its expansion into the sleep market, laying the foundation for its late-stage narcolepsy asset alixorexton.
October 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
December 18, 2025
·
11 min read
Press Releases
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 4, 2025
·
19 min read
Press Releases
Avadel Pharmaceuticals to Present at Upcoming September 2025 Investor Conferences
September 1, 2025
·
1 min read
Press Releases
Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding
September 17, 2025
·
3 min read
Press Releases
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
September 4, 2025
·
13 min read
Press Releases
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - October 13, 2025
October 14, 2025
·
1 min read
Press Releases
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025
September 8, 2025
·
13 min read
1 of 72,080
Next
